Iovance Biotherapeutics (IOVA) Reports 61% Annual Revenue Growth Driven by Amtagvi Success

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the most promising penny stocks under $5 to buy. On February 24, Iovance Biotherapeutics reported earnings for Q4 and the full year 2025, highlighted by a 61% year-over-year increase in total annual revenue to $264 million. Q4 alone generated $87 million in product revenue, representing 30% growth over the previous quarter. This growth was largely driven by the success of Amtagvi, which saw a 112% increase in year-over-year revenue, alongside improved operational efficiency.

On the clinical and regulatory front, Iovance achieved several milestones that support its long-term outlook. The FDA granted Fast Track Designation for lifileucel in non-small cell lung cancer, a move that validates current clinical data and supports a projected 2027 launch for that indication. Additionally, the company reported a promising 50% confirmed response rate in advanced soft tissue sarcomas, with data showing that patient responses are deepening over time.

While management did not provide specific revenue guidance for 2026, they expressed confidence in the company’s expanding pipeline and the gradual ramp-up of community-based Authorized Treatment Centers/ATCs to complement their established academic network. Looking ahead, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is preparing for international market launches and continued data readouts for its combination therapies.

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is a commercial-stage biopharmaceutical company that develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the US and internationally.

While we acknowledge the potential of IOVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.